- Home
- ALGS vs GRCE Comparison
ALGS vs GRCE Comparison
Compare ALGS & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- GRCE
- Stock Information
- Founded
- ALGS 2018
- GRCE 2002
- Country
- ALGS United States
- GRCE United States
- Employees
- ALGS 70
- GRCE N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- GRCE
- Sector
- ALGS Health Care
- GRCE
- Exchange
- ALGS Nasdaq
- GRCE NYSE
- Market Cap
- ALGS 27.9M
- GRCE 32.1M
- IPO Year
- ALGS 2020
- GRCE N/A
- Fundamental
- Price
- ALGS $5.36
- GRCE $2.30
- Analyst Decision
- ALGS Strong Buy
- GRCE Strong Buy
- Analyst Count
- ALGS 1
- GRCE 1
- Target Price
- ALGS $70.00
- GRCE $12.00
- AVG Volume (30 Days)
- ALGS 184.5K
- GRCE 23.2K
- Earning Date
- ALGS 05-06-2025
- GRCE 05-15-2025
- Dividend Yield
- ALGS N/A
- GRCE N/A
- EPS Growth
- ALGS N/A
- GRCE N/A
- EPS
- ALGS N/A
- GRCE N/A
- Revenue
- ALGS $3,945,000.00
- GRCE N/A
- Revenue This Year
- ALGS $580.86
- GRCE N/A
- Revenue Next Year
- ALGS N/A
- GRCE N/A
- P/E Ratio
- ALGS N/A
- GRCE N/A
- Revenue Growth
- ALGS N/A
- GRCE N/A
- 52 Week Low
- ALGS $3.76
- GRCE $1.75
- 52 Week High
- ALGS $46.80
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- ALGS 33.94
- GRCE N/A
- Support Level
- ALGS $4.33
- GRCE N/A
- Resistance Level
- ALGS $5.67
- GRCE N/A
- Average True Range (ATR)
- ALGS 0.78
- GRCE 0.00
- MACD
- ALGS 0.43
- GRCE 0.00
- Stochastic Oscillator
- ALGS 49.61
- GRCE 0.00
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.